UY36678A - Anticuerpos anti-fcrn. - Google Patents
Anticuerpos anti-fcrn.Info
- Publication number
- UY36678A UY36678A UY0001036678A UY36678A UY36678A UY 36678 A UY36678 A UY 36678A UY 0001036678 A UY0001036678 A UY 0001036678A UY 36678 A UY36678 A UY 36678A UY 36678 A UY36678 A UY 36678A
- Authority
- UY
- Uruguay
- Prior art keywords
- fcrn antibodies
- fcrn
- antibody
- dna
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
El invento se relaciona con proteínas de fusión de un anticuerpo específico a FcRn, formulaciones que comprenden el mismo, su uso en terapias, procesos para expresar y opcionalmente formular dicho anticuerpo, ADN que codifica los anticuerpos y anfitriones que comprenden dicho ADN.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1508180.5A GB201508180D0 (en) | 2015-05-13 | 2015-05-13 | Antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36678A true UY36678A (es) | 2016-12-30 |
Family
ID=53489561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036678A UY36678A (es) | 2015-05-13 | 2016-05-13 | Anticuerpos anti-fcrn. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20180127498A1 (es) |
EP (1) | EP3294767A1 (es) |
JP (1) | JP2018516555A (es) |
KR (1) | KR20180002747A (es) |
CN (1) | CN107592867A (es) |
AR (1) | AR104604A1 (es) |
AU (1) | AU2016259720A1 (es) |
BR (1) | BR112017023131A2 (es) |
CA (1) | CA2983770A1 (es) |
CL (1) | CL2017002881A1 (es) |
CO (1) | CO2017011529A2 (es) |
EA (1) | EA201792466A1 (es) |
GB (1) | GB201508180D0 (es) |
IL (1) | IL255323A0 (es) |
MX (1) | MX2017014397A (es) |
TW (1) | TW201706302A (es) |
UY (1) | UY36678A (es) |
WO (1) | WO2016180765A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3087095T (pt) | 2013-12-24 | 2019-10-09 | Argenx Bvba | Antagonistas de fcrn e métodos de utilização |
GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
JP6911490B2 (ja) * | 2017-04-26 | 2021-07-28 | 東ソー株式会社 | 安定型Fc結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤 |
GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
KR20200018643A (ko) * | 2017-06-15 | 2020-02-19 | 유씨비 바이오파마 에스알엘 | 면역 혈소판감소증의 치료 방법 |
EA202091410A1 (ru) * | 2017-12-08 | 2021-01-13 | Ардженкс Бвба | Применение антагонистов fcrn для лечения генерализованной миастении гравис |
MA50586A (fr) * | 2018-08-09 | 2020-09-16 | Regeneron Pharma | Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal |
EA202191231A1 (ru) | 2018-11-06 | 2021-10-11 | Иммуновант Сайенси Гмбх | СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ |
JP2022535908A (ja) | 2019-06-07 | 2022-08-10 | アルジェニクス ビーブイ | 皮下投与に好適なFcRnインヒビターの医薬製剤 |
CN114478800B (zh) * | 2021-02-05 | 2022-10-11 | 华南理工大学 | 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用 |
US11926669B2 (en) | 2022-05-30 | 2024-03-12 | Hanall Biopharma Co., Ltd. | Anti-FcRn antibody or antigen binding fragment thereof with improved stability |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
ES2374068T3 (es) | 2002-12-03 | 2012-02-13 | Ucb Pharma, S.A. | Ensayo para identificar células productoras de anticuerpos. |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
JP2008538919A (ja) | 2005-04-29 | 2008-11-13 | ザ ジャクソン ラボラトリー | FcRn抗体およびその使用 |
CN101370525B (zh) | 2005-08-19 | 2013-09-18 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
EP1986690A4 (en) | 2006-01-25 | 2009-05-13 | Univ New York State Res Found | ANTIBODIES AGAINST FCRN FOR THE TREATMENT OF AUTO / ALLO IMMUNOIDES |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
CN101842387B (zh) | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
BR122021026834B1 (pt) * | 2008-04-25 | 2022-11-08 | Takeda Pharmaceutical Company Limited | Anticorpos isolados que se ligam a fcrn, composição farmacêutica que compreende os mesmos e métodos para detectar e para modular fcrn |
WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
SI2776466T1 (sl) * | 2011-11-11 | 2017-12-29 | Ucb Biopharma Sprl | Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
-
2015
- 2015-05-13 GB GBGB1508180.5A patent/GB201508180D0/en not_active Ceased
-
2016
- 2016-05-09 KR KR1020177034635A patent/KR20180002747A/ko unknown
- 2016-05-09 MX MX2017014397A patent/MX2017014397A/es unknown
- 2016-05-09 WO PCT/EP2016/060305 patent/WO2016180765A1/en active Application Filing
- 2016-05-09 BR BR112017023131A patent/BR112017023131A2/pt not_active Application Discontinuation
- 2016-05-09 JP JP2017558951A patent/JP2018516555A/ja active Pending
- 2016-05-09 CA CA2983770A patent/CA2983770A1/en not_active Abandoned
- 2016-05-09 AU AU2016259720A patent/AU2016259720A1/en not_active Abandoned
- 2016-05-09 EP EP16720869.3A patent/EP3294767A1/en not_active Withdrawn
- 2016-05-09 US US15/573,185 patent/US20180127498A1/en not_active Abandoned
- 2016-05-09 CN CN201680027550.XA patent/CN107592867A/zh active Pending
- 2016-05-09 EA EA201792466A patent/EA201792466A1/ru unknown
- 2016-05-12 AR ARP160101371A patent/AR104604A1/es unknown
- 2016-05-13 TW TW105114957A patent/TW201706302A/zh unknown
- 2016-05-13 UY UY0001036678A patent/UY36678A/es not_active Application Discontinuation
-
2017
- 2017-10-30 IL IL255323A patent/IL255323A0/en unknown
- 2017-11-10 CO CONC2017/0011529A patent/CO2017011529A2/es unknown
- 2017-11-13 CL CL2017002881A patent/CL2017002881A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA201792466A1 (ru) | 2018-06-29 |
WO2016180765A1 (en) | 2016-11-17 |
EP3294767A1 (en) | 2018-03-21 |
BR112017023131A2 (pt) | 2018-07-24 |
IL255323A0 (en) | 2017-12-31 |
CL2017002881A1 (es) | 2018-05-25 |
GB201508180D0 (en) | 2015-06-24 |
MX2017014397A (es) | 2018-04-11 |
TW201706302A (zh) | 2017-02-16 |
AU2016259720A1 (en) | 2017-11-09 |
JP2018516555A (ja) | 2018-06-28 |
CO2017011529A2 (es) | 2018-02-09 |
CA2983770A1 (en) | 2016-11-17 |
CN107592867A (zh) | 2018-01-16 |
KR20180002747A (ko) | 2018-01-08 |
AR104604A1 (es) | 2017-08-02 |
US20180127498A1 (en) | 2018-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36678A (es) | Anticuerpos anti-fcrn. | |
AR107078A1 (es) | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso | |
ECSP17083779A (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos | |
CY1123236T1 (el) | Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3 | |
CL2019000259A1 (es) | Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584) | |
PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
CO2018005436A2 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
ECSP14030789A (es) | Anticuerpos Anti-FcRn | |
CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
BR112018001955A2 (pt) | anticorpos monoclonais contra bcma | |
CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CL2018000479A1 (es) | Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos | |
CL2015002654A1 (es) | Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso | |
UY37523A (es) | Anticuerpos anti-ox40 y sus usos | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
BR112017011932A2 (pt) | ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso? | |
EA201891339A1 (ru) | Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб | |
CR20150482A (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
CR20180013A (es) | Anticuerpos anti-tau y métodos de uso. | |
BR112017011914A2 (pt) | ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso? | |
CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
CL2017003240A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20221114 |